1.278SEK+2.90%Mkt Cap: 29.20M SEKP/E: —Last update: 2026-05-13
Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden. The company's pipeline products include RMC-035, an intact therape…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-0.18
PEG—
P/B0.72
P/S—
EV/EBITDA—
EV/Revenue—
EPS (TTM)-6.04
EPS (Forward)-8.06
Cash Flow & Leverage
FCF Yield-251.65%
FCF Margin—
Operating CF-109.35M SEK
CapEx (TTM)—
Net Debt/EBITDA—
Net Debt-49.83M SEK
Technical
SMA 501.303 (-1.9%)
SMA 2007.453 (-82.9%)
Beta-0.23
S&P 52W Chg24.23%
Avg Vol (30d)53.49K
Avg Vol (10d)69.28K
Technical Indicators
RSI (14)55.7
MACD-0.0329
MACD Signal-0.0750
MACD Hist.+0.0421
BB Upper1.340 SEK
BB Middle1.118 SEK
BB Lower0.8965 SEK
BB Width39.64%
ATR (14)0.1292 SEK
Vol Ratio (20d)0.52x
52W Range
0.88102% of range27.00
52W High27.00 SEK
52W Low0.8810 SEK
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE-267.90%
ROA-201.04%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio5.36
Quick Ratio4.99
Book Value/Sh2.015 SEK
Cash/Share2.471 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateDec 15, 2023
Ownership
Shares Out.20.17M
Float15.93M
Insiders28.67%
Institutions37.01%
Analyst Consensus
Rating—
Target (Mean)1.750 SEK
Target Range1.750 SEK – 1.750 SEK
# Analysts1
Company
Market Cap29.20M SEK
Enterprise Value-20.62M SEK
Revenue (TTM)—
Gross Profit0 SEK
Net Income (TTM)-108.85M SEK
Revenue/Share—
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees12
Last Price1.278 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0009973357